Results 1 to 10 of about 25,524 (191)

Age-Specific Effectiveness of Antiviral Agents on the Secondary Household Transmission of Influenza. [PDF]

Influenza Other Respir Viruses
ABSTRACT Objectives We investigate the effects of age, vaccination history, treatment timing, and type of antiviral agent in index cases and household members on the risk of influenza transmission. Methods We conducted a retrospective household survey in Japan between October 2018 and February 2019, enrolling 915 households (3248 members) with ...
Seo J, Kim J, Nishiura H, Lee H.
europepmc   +2 more sources

Evaluating the effects of oseltamivir phosphate on platelet counts: a retrospective review

Platelets, 2020
Desialylation of platelets results in platelet clearance by the Ashwell-Morrell Receptors (AMR) found on hepatocytes. Studies suggest that oseltamivir phosphate inhibits human sialidases, enzymes responsible for desialylation, extending the lifespan of ...
Sean Yates, Peter McCaffrey
exaly   +2 more sources

Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. [PDF]

PLoS Pathogens, 2010
Influenza viruses resistant to antiviral drugs emerge frequently. Not surprisingly, the widespread treatment in many countries of patients infected with 2009 pandemic influenza A (H1N1) viruses with the neuraminidase (NA) inhibitors oseltamivir and ...
Maki Kiso, Kyoko Shinya, Masayuki Shimojima, Ryo Takano, Kei Takahashi, Hiroaki Katsura, Satoshi Kakugawa, Mai Thi Quynh Le, Makoto Yamashita, Yousuke Furuta, Makoto Ozawa, Yoshihiro Kawaoka   +11 more
doaj   +2 more sources

Genomic and Clinical Analysis of Influenza A in Hospitalized Adults, 2019-2024: Exploratory Evidence on Neuraminidase and Polymerase Acidic Protein Mutation-Outcome Associations From a Single Center. [PDF]

Influenza Other Respir Viruses
ABSTRACT Background Antivirals are widely used to treat influenza, but potential resistance mutations remain a major challenge, and clinical data on key resistance mutations are limited. Methods We conducted a retrospective cohort study of 765 adults with RT‐PCR‐confirmed influenza A admitted to Ruijin Hospital, Shanghai, between 2019 and 2024 to ...
Feng A, Tan W, Xu W, Zhang X, Wei D, Yang Z.   +5 more
europepmc   +2 more sources

Oseltamivir for influenza [PDF]

The Lancet, 2015
124 www.thelancet.com Vol 387 January 9, 2016 declare “no competing interests”, but Dobson’s salary was supported by Roche during the analysis and Pocock told a journalist that he received research funds from Gilead and Genentech. Also, Richard Whitley does not inform readers that Gilead Sciences is the patent holder for oseltamivir so readers can ...
Peter, Doshi, Carl, Heneghan, Tom, Jefferson   +2 more
  +14 more sources

Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. [PDF]

PLoS ONE, 2007
Oseltamivir is the main antiviral for treatment and prevention of pandemic influenza. The increase in oseltamivir resistance reported recently has therefore sparked a debate on how to use oseltamivir in non pandemic influenza and the risks associated ...
Jerker Fick, Rickard H Lindberg, Mats Tysklind, Paul D Haemig, Jonas Waldenström, Anders Wallensten, Björn Olsen   +6 more
doaj   +1 more source

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. [PDF]

PLoS ONE, 2017
Human carboxylesterase 1 (CES1) is a serine esterase that hydrolyses various exogenous and endogenous compounds including oseltamivir, a prodrug used to treat influenza. A novel CES1 c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease
Jaeseong Oh, SeungHwan Lee, Howard Lee, Joo-Youn Cho, Seo Hyun Yoon, In-Jin Jang, Kyung-Sang Yu, Kyoung Soo Lim   +7 more
doaj   +1 more source

A Practical Synthesis of (−)‐Oseltamivir [PDF]

Angewandte Chemie, 2007
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Nobuhiro, Satoh, Takahiro, Akiba, Satoshi, Yokoshima, Tohru, Fukuyama   +3 more
openaire   +2 more sources

Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs.

PLoS Computational Biology, 2022
Oseltamivir is a widely used influenza virus neuraminidase (NA) inhibitor that prevents the release of new virus particles from host cells. However, oseltamivir-resistant strains have emerged, but effective drugs against them have not yet been developed.
Jiaye Tao, Heping Wang, Wenjian Wang, Na Mi, Wei Zhang, Qiujia Wen, Jiajing Ouyang, Xinyun Liang, Min Chen, Wentao Guo, Guoming Li, Jun Liu, Hanning Zhao, Xin Wang, Xuemeng Li, Shengjun Feng, Xinguang Liu, Zhiwei He, Zuguo Zhao   +18 more
doaj   +1 more source

The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study

Saudi Pharmaceutical Journal, 2023
Background: Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce.
Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Meshal S. Alotaibi, Noura A. Alrakban, Ragia H. Ghoneim, Ramesh Vishwakarma, Abdulrahman I. Al Shaya, Shmeylan Al Harbi, Jawaher Gramish, Dahlia M. Almutairi, Ghada Alqannam, Faisal F. Alamri, Abdullah F. Alharthi, Mashael Alfaifi, Abdullah Al Amer, Abeer A. Alenazi, Norah Bin Aydan, Mai Alalawi, Khalid Al Sulaiman   +19 more
doaj   +1 more source